Andrew Shutterly Net Worth

What's Andrew Shutterly's mailing address?

Andrew's mailing address filed with the SEC is C/O ALTIMMUNE, INC.,, 910 CLOPPER ROAD, SUITE 201S, GAITHERSBURG, MD, 20878.

Insiders trading at Altimmune Inc

Over the last 7 years, insiders at Altimmune Inc have traded over $2,557,810 worth of Altimmune Inc stock and bought 3,362,060 units worth $23,898,779 . The most active insiders traders include Bioventures Ltd Novartis Ag..., Healthcare Capital Partners... и Mitchel Sayare. On average, Altimmune Inc executives and independent directors trade stock every 35 days with the average trade being worth of $432,889. The most recent stock trade was executed by David Drutz on 19 August 2024, trading 41,750 units of ALT stock currently worth $106,463.

What does Altimmune Inc do?

altimmune, inc. is a clinical stage biotechnology company developing next-generation immunotherapeutics and vaccines to address significant public health and biodefense needs. by leveraging specific attributes of its two independent and complementary platform technologies, altimmune can rapidly design product candidates against a wide range of disease targets, including respiratory diseases, chronic infections, and cancer. our densigen™ t-cell platform technology is uniquely suited to direct the immune response against traditionally difficult disease targets, including chronic infections and cancer, by directing an individual’s immune system against multiple target antigens instead of just one. altimmune’s respirvec™ platform utilizes convenient needle-free intranasal delivery to achieve broad immunity against disease pathogens more rapidly than conventional vaccines. vaxin’s product candidates are easily manufactured, highly stable, and provide a safe, effective alternative to current

Altimmune Inc executives and stock owners

Altimmune Inc executives and other stock owners filed with the SEC include:

• Dr. Vipin K. Garg Ph.D.,
  Pres, CEO & Director
• William Brown,
  Chief Financial Officer, Principal Accounting Officer
• Dr. Matthew Scott Harris M.D., MS, FCAP, AGAF,
  Chief Medical Officer
• Vipin Garg,
  President, Chief Executive Officer, Director
• Dr. M. Scot Roberts,
  Chief Scientific Officer
• John Gill,
  Independent Director
• M. Scott Harris,
  Chief Medical Officer
• Mitchel Sayare,
  Chairman of the Board
• Ashley Robinson,
  IR Contact Officer
• Klaus Schafer,
  Independent Director
• Wayne Pisano,
  Independent Director
• Philip Hodges,
  Independent Director
• David Drutz,
  Independent Director
• Diane Jorkasky,
  Director
• M. Scot Roberts,
  Chief Scientific Officer
• José Ochoa,
  Chief Bus. Officer
• Bertrand Georges Ph.D.,
  Chief Technology Officer
• Richard I. Eisenstadt M.B.A.,
  CFO and Principal Financial & Accounting Officer
• Sybil Tasker,
  Chief Medical Officer
• Philip Hodges,
  Director
• Derace L Schaffer,
  Director
• Capital S.A.S. Truffle,
  10% owner
• Bioventures Ltd Novartis Ag...,
  
• William Enright,
  President and CEO
• Elizabeth Czerepak,
  CFO and EVP Corp. Development
• Healthcare Capital Partners...,
  
• Pharmaceutical Holdings Llc...,
  10% owner
• Richard I Eisenstadt,
  Chief Financial Officer
• Raymond M Jordt,
  Chief Business Officer
• Catherine A. Sohn,
  Director
• Andrew Shutterly,
  Acting Chief Financial Officer